Physician profile
Mark C Stahl
NPI 1912932476
$50,575.27
in general payments reported to CMS, 2019-2025
40 companies · $6,788 in 2025
The $6,788 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,277 · 2020: $3,468 · 2021: $14K · 2022: $5,868 · 2023: $3,679 · 2024: $7,768 · 2025: $6,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $5,551 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,536.62 |
| Consulting Fee | $5,551.48 |
| Education | $147.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20,768.76 | 2019-2023 | Spiriva Respimat |
| Regeneron Pharmaceuticals, INC. | $3,798.00 | 2024 | Dupixent |
| Genzyme Corporation | $3,576.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,476.98 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $3,415.98 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,803.11 | 2019-2025 | Dupixent |
| Csl Behring | $1,562.09 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $1,371.85 | 2019-2021 | |
| Genentech USA, INC. | $1,185.42 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $918.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $882.34 | 2019-2025 | |
| Alk-Abello, INC | $844.82 | 2019-2025 | Ragwitek, Grastek, Odactra |
| Grifols USA, LLC | $835.06 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $679.27 | 2020-2025 | Cuvitru, Eohilia, Hyqvia |
| Pfizer INC. | $384.68 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $338.46 | 2022-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Amgen INC. | $335.03 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $333.31 | 2022-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $327.93 | 2025 | Neffy |
| Kaleo, INC. | $317.76 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $316.79 | 2019-2025 | Ruconest |
| Shire North American Group INC | $306.67 | 2019 | |
| Incyte Corporation | $287.75 | 2021-2025 | Opzelura |
| Biocryst US Sales Co., LLC | $283.53 | 2021-2023 | Orladeyo |
| Genentech, INC. | $270.28 | 2019-2024 | Xolair |
| Horizon Therapeutics Plc | $202.78 | 2019-2023 | Actimmune |
| Adma Biomanufacturing LLC | $143.77 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $109.96 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $70.46 | 2020-2022 | |
| Gc Biopharma USA, INC. | $66.33 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $62.44 | 2023-2025 | Ryaltris |
| Grifols Shared Services North America, INC. | $55.79 | 2025 | Xembify |
| Jubilant Hollisterstier LLC | $47.16 | 2019 | |
| Mylan Pharmaceuticals INC. | $45.23 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $44.54 | 2025 | Dawnzera |
| Greer Laboratories, INC. | $41.13 | 2021-2024 | Oralair |
| Bio Products Laboratory USA, INC. | $18.61 | 2021 | |
| Organon LLC | $18.54 | 2025 | |
| Lilly USA, LLC | $16.42 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.